Supporting oncology professionals through education
The content on this site is intended for healthcare professionals only
The content on this site is intended for healthcare professionals only
A combination of iza-bren (BL-B01D1), a novel bispecific antibody-drug conjugate (ADC), with osimertinib demonstrated a 100% objective response rate (ORR) in patients with first-line EGFR-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC).
This study was presented today at the International Association for the Study of Lung Cancer 2025 World Conference on Lung Cancer (WCLC).
Iza-bren is a first-in-class ADC combining EGFR and HER3 targeting with a topoisomerase I inhibitor payload. The study tested iza-bren at multiple dose levels in combination with daily osimertinib, a third-generation EGFR tyrosine kinase inhibitor. Among 40 patients treated at 2.5 mg/kg, the ORR was 100% and the confirmed ORR (cORR) was 95.0%, with two partial responses pending confirmation.
“These results are remarkable and suggest that this combination could offer a potentially transformative first-line treatment option for EGFR-mutant NSCLC,” said Dr. Fei Zhou, presenting author from Shanghai East Hospital. “Importantly, the regimen was also manageable from a safety perspective.”
Dr. Zhou and his colleagues enrolled 154 patients who received iza-bren in combination with osimertinib at 2.2, 2.5, 2.75 mg/kg D1D8 Q3W (Day 1 and Day 8 every 3-week cycle) and 4.0, 4.5 mg/kg D1 Q3W (Day 1 every 3-week cycle).
The median follow up was 12.8 months. In the 2.5 mg/kg cohort (n=40), the ORR was 100% and the 12-month progression-free survival rate was 92.1%. Dr. Zhou noted that the median duration of response (DOR) and PFS has not yet reached.
Most treatment-related adverse events (TRAEs) were hematologic, including anemia (91.9%), neutropenia (91.1%), leukopenia (91.1%), and thrombocytopenia (75.6%). Non-hematologic TRAEs included nausea, stomatitis, decreased appetite, vomiting, diarrhea, asthenia, AST increased, ALT increased, hypokalemia, hypoalbuminemia, weight decreased, rash and alopecia. Grade 3 or higher events were manageable with supportive care and dose modifications. The discontinuation rate of iza-bren due to TRAEs was 13.0%.
“Iza-bren in combination with osimertinib has demonstrated promising activity with a manageable safety profile in first-line EGFR-mutated NSCLC patients,” Dr. Zhou reported.
We are an independent charity and are not backed by a large company or society. We raise every penny ourselves to improve the standards of cancer care through education. You can help us continue our work to address inequalities in cancer care by making a donation.
Any donation, however small, contributes directly towards the costs of creating and sharing free oncology education.
Together we can get better outcomes for patients by tackling global inequalities in access to the results of cancer research.
Thank you for your support.